Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EGEN-5784 Porcine Liver With the Metra® ELC Device

NCT: NCT07429838 · NOT_YET_RECRUITING

NCT IDNCT07429838
StatusNOT_YET_RECRUITING
Start Date2026-06
Completion2028-01

Brief Summary

This is a Phase 1, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants with Grade 2 to Grade 3 acute-on-chronic liver failure (ACLF) and hepatic encephalopathy Grade 1-3. The metra® device has been modified for the purposes of cross-circulation with an extra-corporeal porcine liver. The EGEN-5784 liver and metra® ELC device are designed to support liver function during the treatment period

Frequently Asked Questions

What is EGEN-5784 Porcine Liver With the Metra® ELC Device?

EGEN-5784 Porcine Liver With the Metra® ELC Device is a clinical trial registered under NCT07429838. Current status: NOT_YET_RECRUITING.

What is the status of NCT07429838?

The current status of NCT07429838 (EGEN-5784 Porcine Liver With the Metra® ELC Device) is: NOT_YET_RECRUITING.

When did EGEN-5784 Porcine Liver With the Metra® ELC Device start?

EGEN-5784 Porcine Liver With the Metra® ELC Device started on 2026-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑